NCT03027284View on ClinicalTrials.gov

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 3, 2017

Primary Completion Date

June 20, 2019

Study Completion Date

March 17, 2020

Conditions
Advanced CancerMetastatic CancerBiliary Tract CarcinomaCholangiocarcinomaGall Bladder CarcinomaSolid TumorNon-Hodgkin's Lymphoma
Interventions
DRUG

Merestinib

Administered orally

DRUG

Cisplatin

Administered IV

DRUG

Gemcitabine

Administered IV

Trial Locations (2)

277 8577

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Chiba

104-0045

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tokyo

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03027284 - A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer | Biotech Hunter | Biotech Hunter